<?xml version="1.0" encoding="UTF-8"?>
<p id="Par33">In SARS-Cov-2 negative, low-risk individuals, allergen immunotherapy (AIT) should not be stopped and actually can be started in naive patients provided the required infrastructure is in place during the pandemic [
 <xref ref-type="bibr" rid="CR15">15</xref>]. We underline that sublingual immunotherapy (SLIT) for airborne allergens allows not suspending AIT and can be a valid and safe alternative for patients about to undergo SCIT, as far as a drug home-delivering service is activated by the local Pharmacy [
 <xref ref-type="bibr" rid="CR9">9</xref>]. This can prove a fruitful advantage of SLIT over subcutaneous immunotherapy (SCIT), in keeping patients adherent to AIT; transition from SCIT to SLIT might be considered as a possible management strategy during COVID-19 pandemic. SCIT for hymenoptera venom allergy should be continued although increasing administration interval can be considered during long-term maintenance. In confirmed or suspected COVID-19 patients, AIT should not be started and should be temporarily interrupted if already prescribed. AIT-specific recommendations are summarized in TableÂ 
 <xref rid="Tab1" ref-type="table">1</xref> [
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
